Morning Trading March 13, page-61

Endless, I know you are only looking at Neuren from a trader's perspective but, given your pervious comments, hopefully the company has changed your view on ASX biotechs since your post in December 2021:

"Patsy 2 said. "Would love to hear how NEU announcement didn't impress you?"

First thing. I did not say that. I said "recent anncmnt wasn't that amazing."

• Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I) (p=0.0030)

• Trofinetide met key secondary endpoint demonstrating statistically significant improvement over placebo in CSBS-DP-IT–Social (p=0.0064), caregiver scale of ability to communicate.

Best they can say is that the results were 'encouraging'. This was a small study and only had an affect on the symptoms of Retts, not the disease itself. There were still significant side effects. Based on these results I would not think it that likely that this treatment would get FDA approval. (About same chance as Gladys B not getting found guilty of corrupt behaviour in office).

All the guff about how much $$$s is just speculation based on the drug being commercialised. NEU has been going on about stuff like this for years.

I would love this to be a breakthrough as I know peeps dealing with this disorder.

Trader would have sold near $4. imo

And my comments are in the context of there being virtually zero successful bio-med/bio-tech spec stocks on the ASX EVER!"